72 related articles for article (PubMed ID: 2027301)
41. Development of drug resistance in cultured clonogenic leukemic blast cells during the clinical course of myeloblastic leukemia.
Asano Y; Okamura S; Shibuya T; Morioka E; Hirota Y; Niho Y
Oncology; 1989; 46(5):339-42. PubMed ID: 2779949
[TBL] [Abstract][Full Text] [Related]
42. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture.
Fountzilas G; Inoue S; Ohnuma T
Leukemia; 1990 May; 4(5):321-4. PubMed ID: 2388478
[TBL] [Abstract][Full Text] [Related]
43. Effects of interferon and retinoic acid on the growth and differentiation of clonogenic leukemic cells from acute myelogenous leukemia patients treated with recombinant leukocyte-alpha A interferon.
Gallagher RE; Lurie KJ; Leavitt RD; Wiernik PH
Leuk Res; 1987; 11(7):609-19. PubMed ID: 3475513
[TBL] [Abstract][Full Text] [Related]
44. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells.
Bhalla K; Ibrado AM; Tourkina E; Tang C; Grant S; Bullock G; Huang Y; Ponnathpur V; Mahoney ME
Blood; 1993 Nov; 82(10):3133-40. PubMed ID: 8219202
[TBL] [Abstract][Full Text] [Related]
45. Balance between proliferation and apoptosis in leukemic cell lines resistant to cytostatics.
Macnamara B; Palucka KA; Porwit-MacDonald A
Leuk Lymphoma; 1999 Dec; 36(1-2):179-89. PubMed ID: 10613463
[TBL] [Abstract][Full Text] [Related]
46. In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.
Bruserud O; Nesthus I; Pawelec G
Cancer Chemother Pharmacol; 1995; 37(1-2):70-8. PubMed ID: 7497600
[TBL] [Abstract][Full Text] [Related]
47. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences.
Bayever E; Haines KM; Iversen PL; Ruddon RW; Pirruccello SJ; Mountjoy CP; Arneson MA; Smith LJ
Leuk Lymphoma; 1994 Jan; 12(3-4):223-31. PubMed ID: 8167553
[TBL] [Abstract][Full Text] [Related]
48. In vitro effects of interleukin-12 on the growth of blast progenitors in acute myelogenous leukemia.
Miyauchi J
Leukemia; 2001 Dec; 15(12):1996-8. PubMed ID: 11753626
[No Abstract] [Full Text] [Related]
49. Prognostic implications of blast self-renewal capacity in acute myelocytic-leukemia.
Nara N
Int J Oncol; 1993 Aug; 3(2):365-8. PubMed ID: 21573375
[TBL] [Abstract][Full Text] [Related]
50. Biochemical lesions in DNA associated with the antiproliferative effects of mitoxantrone in the hepatoma cell.
Ellis AL; Randolph JK; Conway BR; Gewirtz DA
Biochem Pharmacol; 1990 May; 39(10):1549-56. PubMed ID: 2337411
[TBL] [Abstract][Full Text] [Related]
51. Mitoxantrone sensitivity of human hematopoietic cell lines.
Roos G
Leuk Res; 1987; 11(6):519-24. PubMed ID: 3600027
[TBL] [Abstract][Full Text] [Related]
52. AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
Hagenbeek A; Martens AC
Eur J Cancer Clin Oncol; 1986 Oct; 22(10):1255-8. PubMed ID: 3469100
[TBL] [Abstract][Full Text] [Related]
53. Plasma kinetics of mitoxantrone in leukemic patients.
Hulhoven R; Dumont E; Harvengt C
Med Oncol Tumor Pharmacother; 1984; 1(3):201-4. PubMed ID: 6544900
[TBL] [Abstract][Full Text] [Related]
54. Potentiation of cytotoxicity of mitoxantrone toward CHO-K1 cells in vitro by dipyridamole.
Desai PB; Sridhar R
Pharm Res; 1992 Feb; 9(2):178-81. PubMed ID: 1553337
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness of mitoxantrone on the proliferation of cell cultures derived from malignant mesenchymal tumors of human origin.
Dietel M; Arps H; Gerding D; Trapp M; Sieck M; Niendorf A
J Cancer Res Clin Oncol; 1988; 114(2):197-203. PubMed ID: 3350853
[TBL] [Abstract][Full Text] [Related]
56. A Precise Nanostructure of Folate-Overhung Mitoxantrone DNA Tetrahedron for Targeted Capture Leukemia.
Bu YZ; Xu JR; Luo Q; Chen M; Mu LM; Lu WL
Nanomaterials (Basel); 2020 May; 10(5):. PubMed ID: 32429472
[TBL] [Abstract][Full Text] [Related]
57. Studies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone:
Hrynchak I; Sousa E; de Lourdes Bastos M; Pinto M; Costa VM
Porto Biomed J; 2017; 2(5):220-221. PubMed ID: 32258719
[No Abstract] [Full Text] [Related]
58. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.
Dunn CJ; Goa KL
Drugs Aging; 1996 Aug; 9(2):122-47. PubMed ID: 8820798
[TBL] [Abstract][Full Text] [Related]
59. 1-beta-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation.
Ray S; Ponnathpur V; Huang Y; Tang C; Mahoney ME; Ibrado AM; Bullock G; Bhalla K
Cancer Chemother Pharmacol; 1994; 34(5):365-71. PubMed ID: 7915211
[TBL] [Abstract][Full Text] [Related]
60. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors.
Grant S; Arlin Z; Gewirtz D; Feldman E
Leukemia; 1991 Apr; 5(4):336-9. PubMed ID: 2027301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
